SCHEMBL4240812

SCHEMBL4240812

NC(=O)C(C(=O)Nc1ncc[nH]1)c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 1/20 0.44
▸ HDAC4 P56524 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ RPS6KB1 P23443 5/20 0.39
▸ AURKA O14965 2/20 0.39
▸ ROCK2 O75116 3/20 0.38
▸ PTGES O14684 3/20 0.38
▸ EPHX1 P07099 1/20 0.37
▸ NR3C2 P08235 1/20 0.37
▸ ITGB3 P05106 1/20 0.36
▸ ITGAV P06756 1/20 0.36
▸ AKT1 P31749 2/20 0.36
▸ AURKB Q96GD4 2/20 0.36
▸ INCENP Q9NQS7 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240372 0.87 FFAR2 (0.44) FFAR2RPS6KB1PTGESNR3C2
SCHEMBL4239132 0.85 FFAR2 (0.52) FFAR2RPS6KB1AURKAROCK2PTGES
SCHEMBL4239414 0.85 FFAR2 (0.41) FFAR2AURKAROCK2EPHX1NR3C2
SCHEMBL4242694 0.85 FFAR2 (0.50) FFAR2HDAC4HDAC7HDAC5ROCK2
SCHEMBL4247079 0.84 FFAR2 (0.49) FFAR2PTGESNR3C2ITGB3ITGAV
SCHEMBL4243620 0.81 FFAR2 (0.43) FFAR2PTGES
SCHEMBL4243726 0.78 FFAR2 (0.45) FFAR2HDAC4HDAC7HDAC5ROCK2
SCHEMBL4242107 0.77 FFAR2 (0.53) FFAR2RPS6KB1AURKAPTGESNR3C2
SCHEMBL4239786 0.77 FFAR2 (0.67) FFAR2PTGES
SCHEMBL4240719 0.75 FFAR2 (0.51) FFAR2ROCK2PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US claimed
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 — — US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 — — US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 — — US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 — — EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 — — US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885HDAC4 1331/4885HDAC7 711/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP FFAR2 4632/4885HDAC4 1331/4885HDAC7 711/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885HDAC4 1331/4885HDAC7 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback